

OCT 18 2007

Form PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b> <i>(use several sheets if necessary)</i>				Attorney's Docket No. 39766-0222R1C1D1	Application Serial No. 09/825,584		
				Applicant(s) Akita, et al.			
				Filing Date: April 4, 2001	Group Art Unit: 1643		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
1			5,480,968				
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation
							YES
2			94/02602	WO			
<b>OTHER DOCUMENTS</b> <i>(including author, title, date, pertinent pages, etc.)</i>							
Examiner Initials	Ref. No.	Title					
	3.	C. H. Heldin, Cell, vol. 80, 1995, pp. 213-223					
	4.	Sliwkowski et al., The Journal of Biological Chemistry, vol. 269, 1994, pp. 14661-14665					
	5.	Fiddes, Cell Growth and Differentiation, vol. 6, 1995, pp. 1567-1577					
	6.	Ethier, Cancer Research, vol. 56, 1996, pp. 899-907					
	7.	Lewis et al., Cancer Research, vol. 56, 1996, pp. 1457-1465					
	8.	Rajkumar et al., The Breast, vol. 4, 1995, pp. 84-91					
	9.	Rajkumar and Gullick, Br. J. Cancer vol. 70, 1994, pp. 459-465					
	10.	Kraus et al., Proc. Natl. Acad. Sci. USA, vol. 90, 1993, pp. 2900-2904					
	11.	Zhang et al., The Journal of Biological Chemistry, vol. 271, February 1996, pp. 3884-3890					
	12.	Chen et al., The Journal of Biological Chemistry, vol. 271, 1996, pp. 7620-7629					
	13.	Experimental Report of Dr. Treder					
	14.	CV of Dr. Treder					
	15.	Correspondence from 1993/1994 between Prof. Gullick and other scientists					
	16.	Correspondence between U3 Pharma and the laboratory offering the antibodies used in D12					
	17.	Presta, 1992, Curr. Op. Struct. Biol, vol. 2, pp. 593-596					
	18.	E-mail exchange U3 Pharma/Lab Vision					
	19.	Ullrich and Schlessinger, 1990, Cell, vol. 61, pp. 203-212.					
	20.	Background information from U3 Pharma.					
	21.	Kraus et al, PNAS, vol. 86, 1989, pp. 9193-9197.					
	22.	Carraway and Cantley, Cell, vol. 78, 1994, pp.5-8.					
	23.	"Molekularbiologie der Zelle" Alberts, Bruce, 1995, 3 <sup>rd</sup> edi., pp. 897-899 (German).					

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2309700 v1	

Form PTO-1449  INFORMATION DISCLOSURE STATEMENT  <i>(use several sheets if necessary)</i>		Attorney's Docket No. 39766-0222R1C1D1	Application Serial No. 09/825,584
		Applicant(s)  Akita, et al.	
		Filing Date: April 4, 2001	Group Art Unit: 1643
24.	Wallasch et al., 1995, EMBO J., vol. 14, pp. 4267-4275		
25.	Fendly et al., 1990, Cancer Res., vol. 50, pp. 1550-1558		
26.	Alimandi et al, 1995, Oncogene, vol. 10, pp. 1813-1821		
27.	Declaration of Dr. Nielsen		
28.	Rajkumar and Gullick, 1994, Breast Cancer Research and Treatment, vol 29, pp. 3-9		
29.	Levi et al., 1995, J. Neuroscience, vol. 15, pp. 1329-1340		
30.	Gammet et al, 1995, J. Biol. Chem., vol. 270, pp. 19022-19027		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2309700 v1	